Literature DB >> 1970224

Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder.

C J McDougle1, W K Goodman, L H Price, P L Delgado, J H Krystal, D S Charney, G R Heninger.   

Abstract

Nine of 17 patients with obsessive-compulsive disorder responded when neuroleptic was added to fluvoxamine with or without lithium. Comorbid occurrence of tic spectrum disorders or of schizotypal personality disorder was associated with response. Abnormalities in brain dopamine and serotonin may be implicated in such patients.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1970224     DOI： 10.1176/ajp.147.5.652

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  20 in total

1.  Sulpiride addition in a case of fluvoxamine-refractory obsessive-compulsive disorder without comorbid psychopathology.

Authors:  L Sevincok; A Uslu; H Kaynak; F Dereboy
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 2.  Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?

Authors:  Katharine A Phillips; Dan J Stein; Scott L Rauch; Eric Hollander; Brian A Fallon; Arthur Barsky; Naomi Fineberg; David Mataix-Cols; Ygor Arzeno Ferrão; Sanjaya Saxena; Sabine Wilhelm; Megan M Kelly; Lee Anna Clark; Anthony Pinto; O Joseph Bienvenu; Joanne Farrow; James Leckman
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

3.  Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?

Authors:  Michael G Wheaton; David Rosenfield; Edna B Foa; H Blair Simpson
Journal:  J Consult Clin Psychol       Date:  2015-05-25

4.  Body dysmorphic disorder and social phobia: cross-sectional and prospective data.

Authors:  Meredith E Coles; Katharine A Phillips; William Menard; Maria E Pagano; Christina Fay; Risa B Weisberg; Robert L Stout
Journal:  Depress Anxiety       Date:  2006       Impact factor: 6.505

Review 5.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

6.  Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.

Authors:  A Khullar; P Chue; P Tibbo
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

7.  Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder.

Authors:  A Woods; C Smith; M Szewczak; R W Dunn; M Cornfeldt; R Corbett
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder.

Authors:  Chan-Hyung Kim; Min-Seong Koo; Keun-Ah Cheon; Young-Hoon Ryu; Jong-Doo Lee; Hong-Shick Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-25       Impact factor: 9.236

Review 9.  Current concepts in the pharmacological treatment of obsessive-compulsive disorder.

Authors:  J Zohar; R C Zohar-Kadouch; S Kindler
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 10.  Anxiety disorders. Focus on obsessive-compulsive disorder.

Authors:  L Warneke
Journal:  Can Fam Physician       Date:  1993-07       Impact factor: 3.275
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.